BioD

Canaccord Genuity is pleased to announce that on July 28, 2016, BioD, LLC, a leading developer of allografts from the placental tissue to aid in wound healing, announced its sale to Derma Sciences, Inc. (Nasdaq: DSCI), a publically held company focused on advanced wound and burn care.  Derma Sciences agreed to acquire BioD for an immediate transaction value of $21.3 million in cash and common stock, with a potential total transaction value of $77.8 million.

Canaccord Genuity acted as financial advisor to BioD and its Board of Directors in connection with the transaction.

BioD, headquartered in Memphis, Tennessee, researches and commercializes biologic products derived from human placental tissues. The Company’s research and development efforts are focused on the regenerative potential of amnion and the other placental tissues given their unique biologic structure, source of undifferentiated stem cells and the unique immune privilege that characterizes their function in the body.